Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents

This publication has 35 references indexed in Scilit:

• PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection
  HIV Medicine, 2002
• Sustained CD4⁺T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus Infection
  The Journal of Infectious Diseases, 2000
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
  The Lancet, 1999
• Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection
  JAMA, 1998
• A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection
  Published by American Academy of Pediatrics (AAP) ,1998
• Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
  The Lancet, 1998
• A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus
  The Journal of Pediatrics, 1998
• CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
  The Lancet, 1998
• Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors
  The Pediatric Infectious Disease Journal, 1997
• A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
  New England Journal of Medicine, 1997